Literature DB >> 22863915

New cancer immunotherapy using autologous lymphocytes activated with trastuzumab.

Shinichirou Nakagawa1, Yusuke Matsuoka, Hideaki Ichihara, Hitoji Yoshida, Kenshi Yoshida, Ryuichi Ueoka.   

Abstract

It is well known that trastuzumab (TTZ) is molecular target drug for breast cancer overexpressing human epidermal growth factor receptor 2 (HER2). Novel immunotherapy by human peripheral blood mononuclear cells (PBMCs) activated with TTZ were examined. Proliferation of lymphocytes after adding of TTZ was obtained. Furthermore, lymphocytes activated with TTZ inhibited growth of breast cancer cells in vitro. It is noteworthy that remarkably high cellular cytotoxicity in lymphocytes activated with TTZ compared with that of CD3- and lymphokine (interleukin (IL)2)-activated killer (CD3-LAK) cells commonly used in immunotherapy were revealed.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22863915     DOI： 10.1248/bpb.b12-00378

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN： 0918-6158            Impact factor:   2.233


  5 in total

1.  Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy.

Authors:  Huiying Yu; Wei Chen; Changling Li; Di Lin; Junde Liu; Zien Yang; Jingang Yang; Yinghui Sun; Dongchu Ma
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

2.  Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system.

Authors:  Tao Yang; Wenjun Zhang; Li Wang; Chunyan Xiao; Li Wang; Yi Gong; Dehong Huang; Bingling Guo; Qiying Li; Ying Xiang; Yingyu Nan
Journal:  BMC Cancer       Date:  2018-10-16       Impact factor: 4.430

3.  Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer.

Authors:  Hansong Du; Jia Yang; Ying Zhang
Journal:  BMC Cancer       Date:  2020-04-28       Impact factor: 4.430

4.  Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2.

Authors:  Xiao Tian; Feng Wei; Limei Wang; Wenwen Yu; Naining Zhang; Xinwei Zhang; Ying Han; Jinpu Yu; Xiubao Ren
Journal:  Front Immunol       Date:  2017-10-30       Impact factor: 7.561

5.  Editorial: Cellular Therapies in Cancer.

Authors:  Hind Rafei; Rohtesh S Mehta; Katayoun Rezvani
Journal:  Front Immunol       Date:  2019-11-27       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.